Generex Biotechnology Corporation (NASDAQ: GNBT) announced today that the Chief Scientific Officer of Antigen Express, Inc., its wholly owned immunotherapeutics subsidiary, made a presentation earlier today at a national conference regarding the Company’s program for accelerated development of its novel vaccine for pandemic influenza.
